Oncothyreon Inc
2601 Fourth Avenue
Suite 500
Seattle,
WA 98121
United States - Map
Phone: 206-801-2100
Fax: 206-801-2101
Web Site: http://www.oncothyreon.com
| Oncothyreon Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing therapeutic products for the treatment of cancer. The companys lead product candidate includes Stimuvax, a cancer vaccine in Phase III development for non-small cell lung cancer. Its pipeline of clinical and pre-clinical stage proprietary small molecule product candidates comprise PX-478, a Phase I trial product, which is a small molecule inhibitor of hypoxia inducible factor-1a for advanced metastatic cancer; PX-866, an inhibitor of the phosphatidylinositol-3-kinase /PTEN/Akt pathway indicated for advanced solid tumors and glioma; PX-12, a Phase II trial product for pancreatic cancer; and PX-316, a chemical inhibitor that prevents translocation, the movement of the target protein in the cell to its site of activation. In addition, the company offers BGLP40 Liposome Vaccine, a preclinical stage liposomal glycolipopeptide cancer vaccine for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, and prostate, as well as various types of lung cancer. The company has strategic collaboration with Merck KGaA for the clinical development and marketing of Stimuvax. Oncothyreon Inc. was founded in 1985 and is headquartered in Bellevue, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Robert Kirkman M.D., 59
Chief Exec. Officer, Pres |
$
551.00K | N/A | Mr. Gary Christianson , 53
Chief Operating Officer |
$
340.00K | N/A | Mr. Shashi K. Karan , 54
Principal Financial Officer, Principal Accounting Officer, Sec. and Corp. Controller |
N/A
| N/A | Mr. Terry Harris ,
Director of HR |
N/A
| N/A | Dr. Scott Peterson Ph.D.,
VP of R&D |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
